Patents Represented by Attorney Xu Zhang
-
Patent number: 8333990Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: September 13, 2010Date of Patent: December 18, 2012Assignee: Abbott LaboratoriesInventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Patent number: 8309613Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: September 13, 2010Date of Patent: November 13, 2012Assignee: AbbVie Inc.Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Patent number: 8268349Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: April 18, 2012Date of Patent: September 18, 2012Assignee: Abbott LaboratoriesInventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Patent number: 8232246Abstract: Compounds capable of inhibiting replication of the hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: GrantFiled: June 30, 2009Date of Patent: July 31, 2012Assignee: Abbott LaboratoriesInventors: Keith F. McDaniel, Dale J. Kempf
-
Patent number: 8197829Abstract: The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.Type: GrantFiled: May 29, 2001Date of Patent: June 12, 2012Assignee: Abbott LaboratoriesInventors: Gunther Berndl, Jörg Breitenbach, Robert Heger, Michael Stadler, Peter Wilke, Jörg Rosenberg
-
Patent number: 8193367Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.Type: GrantFiled: December 22, 2009Date of Patent: June 5, 2012Assignee: Abbott LaboratoriesInventors: John F. Bauer, Azita Saleki-Gerhardt, Bikshandarkoil A. Narayanan, Sanjay R. Chemburkar, Ketan M. Patel, Harry O. Spiwek, Philip E. Bauer, Kimberly A. Allen
-
Patent number: 8025899Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: August 25, 2004Date of Patent: September 27, 2011Assignee: Abbott LaboratoriesInventors: Gunther Berndl, Joerg Rosenberg, Bernd Liepold, Joerg Breitenbach, Ulrich Reinhold, Laman Alani, Soumojeet Ghosh
-
Patent number: 7981911Abstract: Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.Type: GrantFiled: July 31, 2008Date of Patent: July 19, 2011Assignee: Abbott LaboratoriesInventors: Laman Alani, Soumojeet Ghosh
-
Patent number: 7968707Abstract: A compound of the formula: is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.Type: GrantFiled: February 27, 2007Date of Patent: June 28, 2011Assignee: Abbott LaboratoriesInventors: Hing Leung Sham, Daniel W. Norbeck, Xiaoqi Chen, David A. Betebenner, Dale J. Kempf, Thomas R. Herrin, Gondi N. Kumar, Stephen L. Condon, Arthur J. Cooper, Daniel A. Dickman, Steven M. Hannick, Lawrence Kolaczkowski, Patricia A. Oliver, Daniel J. Plata, Peter J. Stengel, Eric J. Stoner, Jieh-Heh J. Tien, Jih-Hua Liu, Ketan M. Patel
-
Patent number: 7915411Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.Type: GrantFiled: December 20, 2006Date of Patent: March 29, 2011Assignee: Abbott LaboratoriesInventors: David A. Betebenner, David A. DeGoey, Clarence J. Maring, Allan C. Krueger, Nobuhiko Iwasaki, Todd W. Rockway, Curt S. Cooper, David D. Anderson, Pamela L. Donner, Brian E. Green, Dale J. Kempf, Dachun Liu, Keith F. McDaniel, Darold L. Madigan, Christopher E. Motter, John K. Pratt, Jason P. Shanley, Michael D. Tufano, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu, David J. Grampovnik
-
Patent number: 7910595Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.Type: GrantFiled: December 20, 2006Date of Patent: March 22, 2011Assignee: Abbott LaboratoriesInventors: David A. Betebenner, David A. DeGoey, Clarence J. Maring, Allan C. Krueger, Nobuhiko Iwasaki, Todd W. Rockway, Curt S. Cooper, David D. Anderson, Pamela L. Donner, Brian E. Green, Dale J. Kempf, Dachun Liu, Keith F. McDaniel, Darold L. Madigan, Christopher E. Motter, John K. Pratt, Jason P. Shanley, Michael D. Tufano, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu, David J. Grampovnik
-
Patent number: 7834043Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.Type: GrantFiled: December 9, 2004Date of Patent: November 16, 2010Assignee: Abbott LaboratoriesInventors: David A. DeGoey, Charles A. Flentge, William J. Flosi, David J. Grampovnik, Dale J. Kempf, Larry L. Klein, Ming C. Yeung, John T. Randolph, Xiu C. Wang, Su Yu
-
Patent number: 7763731Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.Type: GrantFiled: December 20, 2006Date of Patent: July 27, 2010Assignee: Abbott LaboratoriesInventors: Todd W. Rockway, David A. Betebenner, Allan C. Krueger, Nobuhiko Iwasaki, Curt S. Cooper, David D. Anderson, Dale J. Kempf, Darold L. Madigan, Christopher E. Motter, Jason P. Shanley, Michael D. Tufano, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie VL. Masse, Robert J. Carrick, Wenping He, Liangjun Lu
-
Patent number: 7659405Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.Type: GrantFiled: September 21, 2006Date of Patent: February 9, 2010Assignee: Abbott LaboratoriesInventors: John F. Bauer, Azita Saleki-Gerhardt, Bikshandarkoil A. Narayanan, Sanjay R. Chemburkar, Ketan M. Patel, Harry O. Spiwek, Philip E. Bauer, Kimberly A. Allen